Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$88.76 USD
-0.24 (-0.27%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $88.76 0.00 (0.00%) 6:52 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$88.76 USD
-0.24 (-0.27%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $88.76 0.00 (0.00%) 6:52 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Sanofi (SNY) beats earnings but misses on sales in the second quarter of 2018 owing to currency headwinds and struggling diabetes and cardiovascular unit.
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan
by Zacks Equity Research
Allergan (AGN) beats second-quarter estimates for earnings and sales and raises its full-year outlook for both the metrics. The board authorizes a new $2.0 billion share buyback plan.
AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.
Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up
by Zacks Equity Research
ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.
Microsoft, H&R Block, Facebook, Qualcomm and Gilead highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Microsoft, H&R Block, Facebook, Qualcomm and Gilead highlighted as Zacks Bull and Bear of the Day
Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit
by Zacks Equity Research
Gilead's GILD) stock is down in after-market trading as the news of departure of the company's CEO has overshadowed the company's second-quarter results, which beat estimates.
Facebook Misses 1st Time in 11 Quarters; Plus GILD, QCOM
by Mark Vickery
Facebook has posted a one-penny miss, but revenues also came in lower than expected.
Gilead Sciences (GILD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 23.23% and 9.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug
by Zacks Equity Research
The biotech sector is in focus as bigwig Biogen gains on better-than-expected Q2 results. Others like Gilead, Amgen and Celgene too are slated to report shortly.
Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?
by Zacks Equity Research
Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret, might lead the company to an earnings beat in the second quarter.
Is a Beat in Store for Keryx (KERX) This Earnings Season?
by Zacks Equity Research
Keryx (KERX) is likely to provide updates on the merger with Akebia along with the updates on Auryxia at the second quarter call.
Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK
by Zacks Equity Research
The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.
Implied Volatility Surging for Gilead Sciences (GILD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Gilead Sciences (GILD) stock based on the movements in the options market lately.
Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?
by Zacks Equity Research
Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion is likely to provide details about the pipeline portfolio when it reports its second-quarter 2018 results on Jul 26.
Healthcare ETFs to Buy on Solid Q2 Earnings Expectations
by Sweta Killa
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 9.1% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Amgen (AMGN) to Report Q2 Earnings: Will it Beat Again?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?
by Zacks Equity Research
Gilead (GILD) is likely to beat expectations in the second quarter propelled by the momentum in the HIV franchise.
4 Biotech Bets to Watch as Industry Rebounds in a Month
by Madhu Goel
The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.
5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.
J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod
by Zacks Equity Research
The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.
The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna
Is Invesco Zacks Multi-Asset Income ETF (CVY) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CVY
Biotech ETFs Surge on Biogen's Positive Drug Trial Result
by Sweta Killa
Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.